Table 1

Summary of baseline demographics and clinical characteristics of all patients who were treated in year 2

Open-label period (year 2)
Abatacept plus methotrexate (N=232)Methotrexate (N=227)Total (N=459)
Age, years (mean (SD))49.9 (12.2)49.2 (12.7)49.5 (12.5)
Gender (% female)76.378.077.1
Race (% white)78.986.882.8
Geographical region (n (%))
 North America41 (17.7)34 (15.0)75 (16.3)
 South America93 (40.1)94 (41.4)187 (40.7)
 Europe82 (35.3)85 (37.4)167 (36.4)
 Rest of world16 (6.9)14 (6.2)30 (6.5)
Disease duration (mean (months))6.1 (7.5)6.9 (7.1)6.5 (7.3)
Tender joints (mean (SD))31.2 (14.8)30.5 (13.9)30.9 (14.4)
Swollen joints (mean (SD))22.8 (11.2)22.0 (10.4)22.4 (10.8)
CRP levels, mg/dl (mean (SD))3.1 (3.1)3.6 (5.1)3.4 (4.2)
DAS28 (CRP)* (mean (SD))6.3 (1.0)6.3 (1.0)6.3 (1.0)
HAQ-DI (0–3)* (mean (SD))1.7 (0.6)1.7 (0.7)1.7 (0.7)
RF positive (n (%))223 (96.1)220 (96.9)443 (96.5)
Anti-CCP2 positive (n (%))215 (92.7)199 (87.7)414 (90.2)
Total score (maximum 290) (mean (SD))7.7 (9.4)7.2 (8.8)7.5 (9.1)
Erosion score (maximum 145) (mean (SD))5.9 (6.4)5.5 (5.8)5.7 (6.1)
Joint-space narrowing (mean (SD))1.8 (3.8)1.7 (3.8)1.8 (3.8)
  • * n=226 for methotrexate.

  • n=217 for abatacept plus methotrexate; n=200 for methotrexate.

  • Anti-CCP2, anti-cyclic citrullinated peptide type 2; CRP, C-reactive protein; DAS28, 28-joint disease activity score; HAQ-DI, health assessment questionnaire disability index; RF, rheumatoid factor.